Ann: Appendix 3Y-Dr Geoffrey Brooke, page-6

Everyone applauded Fauci amongst the madness. Alas, as is so often the case, in having to counter the morons, he made RCT's the unviersal gold standard (literally said those very words) where sometimes they are not. We now live in a world where mock surgeries are approved by medical ehtical bodies overseeing trials, that they feel are justified in the RCT ideal.

You think getting nothing a hard break. Imagine going into a surgery trial knowing you might just end up with pain, a scar and.....nothing.

The world is a messed up place and alas stricter and harder to recruit RCT's are now a necessary hardship bio-tech companies face. Two steps back one step forward.

JB1975 as usual writes a broad essay of complaint with some very drastic assumptions that are opinion "Share prices in Mesoblast are rising on BS frankly and fools with no clue about the underlying science and tech of either CYP or MSB are moving the share price up irrationally". His comments on the complacent issuing of options is not invalid, but it is an issue the world wide with capital mkts and Director awards across the board. Not Just CYP.

He is not entirely wrong about the stupidiy of investors, the SEC only worked out in the 1990's that Directors were doing a remarkeable job of issuing themselve options strike on the lows (a $100 dollar company that saw a range of $50-150, remarkeably most Direcrtors got $50 striked call options) and it was only after investigation did they realise the crooked Directors determining the strikes after the event and dumb*ss investors not contesting it - and massive ensuing dilution for them and riches for Directrors.

Do be intelligent investors and have a good think about option awards that should only align Director gains with shareholder gains (i.e. higher strikes) before lazily looking by it on your AGM votes on remuneration. Goes for all your investments, not just CYP.